10th NAFLD Study Group Meeting 2022 (3rd virtual)

Thursday 12 – Friday 13 May 2022
16:00-19:00 CET (i.e. Italy)

Mitochondria, Biomarkers, and Treatment of NAFLD

Thursday, May 12

NASH and the redox state

Chair Catherine Postic

16:05 Jennifer Rieusset, Lyon, France - A new role of endoplasmic reticulum-mitochondria calcium coupling in hepatic insulin resistance and steatosis during MAFLD
16:25 Panu Luukkonen, Helsinki, Finland - NASH and the intramitochondrial redox state
16:50 Mingfeng Xia, Shanghai, China - Altered redox state predicts NASH in Chinese

17:10 Break

New Insights into circulating and imaging Biomarkers

Chair Amalia Gastaldelli

17:25 Sami Qadri, Helsinki, Finland - Impact of obesity on biomarker performance in NAFLD
17:55 Detlef Schuppan, Mainz, Germany - Multiprotein platforms and biomarkers of NAFLD
18:25 Claude B Sirlin, San Diego, CA, USA - Recent advances in MRE in identifying features of NAFLD
18:50 End of Day 1

Friday, May 13

Diet and NAFLD

Chair Hannele Yki-Järvinen

16:00 Roy Taylor, Newcastle, UK (20+5 min) - Thresholds for metabolic effects of excess liver fat across the BMI range (ReTUNE and DiRECT trials)
16:25 Shira Zelber-Sagi, Tel-Aviv, Israel - Lessons from recent dietary intervention trials
16:50 Kitt Petersen, Yale, USA - Mechanisms underlying effects of caloric restriction in NAFLD

17:15 Break

Update on pharmacotherapy of NASH

Chair Bart Staels

17:30 Sven Francque, Edegem, Belgium - PPAR agonists: successes and failures
17:55 Vlad Ratziu Paris, France - Update on therapeutic targets into clinical development
18:20 Closing remarks

For further information contact :

← Return